Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008

NCT01903733

About this Study

The objective of the study is to provide long term access to bosutinib treatment and assess
long term safety, tolerability and duration of clinical benefit, without any formal
hypothesis testing; therefore, there is no formal primary endpoint.

Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008

Official Title ICMJE

An Open-label Bosutinib Treatment Extension Study For Subjects With Chronic Myeloid Leukemia (Cml) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008

Brief Summary

The objective of the study is to provide long term access to bosutinib treatment and assess long term safety, tolerability and duration of clinical benefit, without any formal hypothesis testing; therefore, there is no formal primary endpoint.

Detailed Description

Not Provided

Study Type ICMJE

Interventional

Study Phase

Not Provided

Study Design ICMJE

Masking: None (Open Label)

Condition ICMJE

Chronic Myeloid Leukemia

Intervention ICMJE

Drug: bosutinib

The starting bosutinib dose is 500 mg once daily, however the dose can vary from 300 mg to 600 mg.

Study Arms

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.